Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease

NCT06818266 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

130

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease
Acute Chest Syndrome

Interventions

DRUG: Tocilizumab (RoActemra®, 20 mg/mL).
DRUG: Placebo (NaCl 0.9%)

Sponsor

Assistance Publique - Hôpitaux de Paris